Nimotuzumab Plus Concurrent Chemoradiotherapy Improved Response, Survival for Patients With Locally Advanced Cervical Cancer
According to results from a phase 3 study, nimotuzumab combined with concurrent chemoradiotherapy (CCRT) showed improvements in object response rate and progression-free survival, and good safety among patients with locally advanced cervical cancer.
These results were first presented by Junjie Wang, MD, Peking University Third Hospital, Beijing, China, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.
In the randomized, controlled, multicenter, phase 3 CC3 study, 286 patients with locally advanced cervical squamous cell carcinoma were randomized on a 1-to-1 basis to receive either 400 mg nimotuzumab weekly for 6 weeks combined with CCRT (n = 142), or CCRT alone (n = 144). The CCRT regimen was cisplatin weekly for 6 weeks, IMRT/VMAT, and high-dose brachytherapy in 8 weeks. The primary end point was progression-free survival (PFS) rate at 3 years. Secondary end points included overall survival (OS) rates at 3 years, objective response rate (ORR), complete response (CR) rate, and safety.
The PFS rate at 1 year was 96.1% in the nimotuzumab arm vs 92.1% in the CCRT alone arm (P = .506). There were no significant difference in the risk ratio between the 2 arms (hazard ratio, 0.76; P = .507). The 3-year PFS and OS rates were not reached. The ORR in the nimotuzumab arm was 83.80% with 62 partial and 57 complete responses. The ORR in the CCRT along arm was 74.31%, with 50 partial and 57 complete responses. The most common adverse events were grade 1/2 and were consistent with the previously reported safety profile.
Dr Wang concluded, “The combination therapy of nimotuzumab and concurrent chemoradiotherapy represents a promising option for this population.”
Source:
Wang JJ, Jiang P, Qu A, et al. Nimotuzumab plus concurrent chemoradiotherapy for locally advanced cervical squamous cell carcinoma: The randomized, phase 3 CC3 study. Presented at the 2024 ASCO Annual Meeting. May 31-June 4, 2024; Chicago, IL. Abstract #5514
